Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial-Reference-Cited by-同舟云学术

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

Published:2019-01 Issue:10166 Volume:393 Page:40-50
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Gillison Maura L,Trotti Andy M,Harris Jonathan,Eisbruch Avraham,Harari Paul M,Adelstein David J,Jordan Richard C K,Zhao Weiqiang,Sturgis Erich M,Burtness Barbara,Ridge John A,Ringash Jolie,Galvin James,Yao Min,Koyfman Shlomo A,Blakaj Dukagjin M,Razaq Mohammed A,Colevas A Dimitrios,Beitler Jonathan J,Jones Christopher U,Dunlap Neal E,Seaward Samantha A,Spencer Sharon,Galloway Thomas J,Phan Jack,Dignam James J,Le Quynh Thu

Funder

US National Cancer Institute: NRG Oncology Operations

NRG Oncology Statistics and Data Management Center

National Cancer Institute Community Oncology Research Programme

NRG Specimen Bank

Publisher

Elsevier BV

Subject

General Medicine

Reference33 articles.

1. Human papillomavirus and survival of patients with oropharyngeal cancer;Ang;N Engl J Med,2010

2. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17 346 patients;Pignon;Radiother Oncol,2009